Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans.

@article{Gelder1998BlockadeOT,
  title={Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans.},
  author={Teun van Gelder and Carla C. Baan and Aggie H. M. M. Balk and Christiaan J Knoop and C{\'e}cile T. J. Holweg and Peter van der Meer and Bas Mochtar and Pieter E. Zondervan and Hubert G. M. Niesters and Willem W Weimar},
  journal={Transplantation},
  year={1998},
  volume={65 3},
  pages={405-10}
}
BACKGROUND Anti-interleukin (IL)-2 receptor (IL-2R) antibodies have been used as rejection prophylaxis after organ transplantation. Despite this induction treatment, acute rejections may occur. We wondered whether these rejections developed via the IL-2/IL-2R pathway. METHODS In a prospective trial using BT563, a murine IgG1 anti-IL-2R antibody, for rejection prophylaxis after heart transplantation, 20 patients were treated in combination with cyclosporine from the day of transplantation… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

New immunosuppressive drugs in heart transplantation

Current controlled trials in cardiovascular medicine • 2001
View 5 Excerpts
Highly Influenced

Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 1999

Newer immunosuppressive drugs: a review.

Journal of the American Society of Nephrology : JASN • 1999

Similar Papers

Loading similar papers…